Percheron Therapeutics LimitedASX: PER

ATL1102 for MS FDA Response to Phase IIb Study Plans

Mar 30, 2016 at 8:01 AM UTC · Issued by Percheron Therapeutics Limited

Percheron Therapeutics Limited has released a press release.

View Attachment